| HOME >> MEDICINE >> TECHNOLOGY |
Table 14: Russia - a range of pricing and reimbursement tools are used 64
Table 15: Russia - sales and volume of the pharmaceutical market ($ and IMS Standard Units), 2009 75
Table 16: Russia - pharmaceutical sales ($m), 2009 75
Table 17: Russia - pharmaceutical sales by therapy area ($m and %), 2005-09 77
Table 18: Russia - pharmaceutical volume by therapy area (SUm and %), 2005-09 78
Table 19: Russia - sales growth for top 20 pharmaceutical brands ($m and %), 2009 81
Table 20: Russia - volume growth for top 20 pharmaceutical brands (SUm and %), 2009 82
Table 21: Russia - sales growth for the leading international pharmaceutical companies ($ and %), 2009 86
Table 22: Russia - volume growth for the leading international pharmaceutical companies (SU and %), 2009 87
Table 23: Russia - sales growth for the leading Russia-based pharmaceutical companies ($ and %), 2009 88
Table 24: Russia - volume growth for the leading Russia-based pharmaceutical companies (SU and %), 2009 89
Table 25: Russia - key metrics for the generics and biosimilars market, 2010 92
Table 26: Russia - comparison of generic penetration versus other major pharmaceutical markets ($ billion and %), 2007-08 93
Table 27: Russia - leading generics companies, 2008-09 102
Table 28: Russia - brands exposed to generic competition, 2010-13 105
Table 29: Russia - biosimilars registered in Russia, 2009 117
Table 30: Russia - sales (based on 2009 sales data) of original biologics both expired and expected to come off-patent in the five major EU markets (Germany, France, Spain, Italy and UK) 2010-15 121
Table 31: Russia - sales of branded monoclonal antibodies, 2008-09 123
Table 32: Russia - sales growth for the top 10 pharmaceutical companies ($ and %), 2009 130
Table 33: Russia - Novartis's R&D and manufacturing infrastructure, 2010 131
Table 34: Russia - Nov
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |